Thiopurine drugs, such as azathioprine and mercaptopurine, are widely used as immunosuppressants in gastroenterology, dermatology and post-transplant etc. Thiopurine drugs are metabolised by two major pathways — by the enzyme xanthine oxidase and thiopurine S-Methyl-transferase (TPMT). Individual patients vary greatly in susceptibility to the toxic effects of these drugs, due to genetic differences in drug metabolism. TPMT is absent in approximately 1 in 300 people, and around 11% of the population have low activity. Patients who fall into these categories are at risk of severe side-effects. The measurement of TPMT levels at the start of thiopurine therapy allows the dose of thiopurine drugs to be adjusted appropriately for successful treatment.
In addition to TPMT activity detemination, genetic analysis is also carried out. To date more than 20 single-nucleotide polymorphisms (SNP) have been associated with decreased TPMT activity. The most common defects leading to inactivated alleles are G238C mutation in exon 5 (TPMT*2), point mutations in A719G in exon 10 and G460A in exon 7 (TPMT*3A), and an isolated mutation in position A719G (TPMT*3C). These cause rapid degradation of the protein by an ATP dependent proteosome mediated pathway, resulting in loss of catalytic activity of the enzyme.
Patient should not have had recent blood transfusions (both phenotype and genotype results affected).
TPMT activity should be determined BEFORE starting on thiopurine drugs
Drugs such as aziathioprine have been reported to induce TPMT activity, and sulfasalazines can inhibit TPMT activity.
Renal impairment can cause false elevations in TPMT activity
Copyright UHB Pathology 2018
Protection of Personal Information – Clinical Laboratory Services comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
University Hospitals Birmingham medical laboratories at Queen Elizabeth Hospital, Heartlands Hospital, Good Hope Hospital and Solihull Hospital are UKAS (United Kingdom Accreditation Service) accredited to the ISO 15189:2012 standard. For a list of accredited tests and other information please visit the UKAS website using the following link: https://www.ukas.com/find-an-organisation/
Tests not appearing on the UKAS Schedule of Accreditation currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further test information, please visit the test database: http://qehbpathology.uk/test-database
For further information contact Louise Fallon, Quality Manager, 0121 371 5962